Key result
Elevated atherogenic index of plasma is linked to ~75% higher risk of cardiometabolic multimorbidity.
Why the study?
The relationship between atherogenic index of plasma (AIP) and cardiometabolic multimorbidity (CMM) had not been elucidated, including the mediating role of non-HDL cholesterol.
Is an elevated baseline atherogenic index of plasma (AIP) associated with an increased risk of new-onset cardiometabolic multimorbidity in middle-aged and older Chinese adults, and does non-HDL cholesterol mediate this association?
Cohort (n=8,902)
Yes
Is an elevated baseline atherogenic index of plasma (AIP) associated with an increased risk of new-onset cardiometabolic multimorbidity in middle-aged and older Chinese adults, and does non-HDL cholesterol mediate this association?
Answers are grounded in this paper and cite their sources.
Elevated atherogenic index of plasma (AIP) is independently associated with a higher risk of developing cardiometabolic multimorbidity in middle-aged and older Chinese adults, with non-HDL-C mediating approximately a quarter of this risk, highlighting both indices as valuable targets for early risk stratification and lipid-lowering prevention.
The atherogenic index of plasma (AIP) has recently been proposed as a novel indicator of dyslipidemia and is closely associated with the risk of cardiovascular disease. However, the relationship between AIP and cardiometabolic multimorbidity (CMM) has not been elucidated. This study aimed to determine the association between AIP and new-onset CMM, and to analyze the mediating role of non-high-density lipoprotein cholesterol (non-HDL-C) in this relationship. Data were obtained from the China Health and Retirement Longitudinal Study (CHARLS). A total of 8,902 middle-aged and older adults (≥ 45 years of age) without CMM at baseline in 2011 were enrolled and followed until 2020. The baseline AIP level was the exposure variable, the baseline non-HDL-C level was the mediator, and new-onset CMM during the 2011–2020 follow-up period was the outcome variable. Cox proportional hazards models were used to evaluate the association between AIP and CMM. Bootstrap methods were used for mediation analysis to determine the mediating effect of non-HDL-C and subgroup analyses were performed to assess the robustness of the findings. By the end of follow-up in 2020, 883 participants (9.92%) had developed new-onset CMM. After full adjustment for confounders, each one-unit incremental increase in AIP was associated with a 70.9% increased risk of CMM (HR = 1.709, 95% CI: 1.399–2.087). Participants in the highest quartile had a 75.4% increased risk of CMM compared to the lowest AIP quartile (HR = 1.754, 95% CI: 1.410–2.183). Non-HDL-C partially mediated the association between AIP and CMM, accounting for 25.53% of the total effect (indirect effect, β = 0.014, 95% CI: 0.006–0.022, P < 0.001). Sensitivity analyses that excluded early CMM events or participants who died during follow-up yielded consistent results, which confirmed the robustness of our primary findings. Subgroup analyses indicated consistent associations across strata of age, sex, body mass index, hypertension, and lifestyle factors. An elevated AIP was independently associated with an increased risk of new-onset CMM among middle-aged and older Chinese adults with non-HDL-C partially mediating this association. AIP may serve as a reference indicator for identifying populations at high risk of CMM and provide insights for early prevention strategies.
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) conducted a cohort in Cardiometabolic multimorbidity (CMM) (n=8,902). Elevated atherogenic index of plasma (AIP, highest quartile Q4 or per 1-unit incremental increase) vs. Lowest quartile (Q1) of atherogenic index of plasma (AIP) was evaluated on New-onset cardiometabolic multimorbidity (CMM, defined as coexistence of ≥2 of stroke, heart disease, and diabetes) (HR 1.754, 95% CI 1.410-2.183, p=<0.001). Elevated atherogenic index of plasma (Q4 vs Q1) increased the risk of new-onset cardiometabolic multimorbidity by 75.4%, with non-HDL-C mediating 25.53% of the effect.
Synapse has enriched 10 related papers. Consider them for comparative context: